Sionna Therapeutics (SION) Operating Leases (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Operating Leases data on file, last reported at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 15.79% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (down 15.79% YoY), and the FY2025 full-year result was $7.4 million, down 14.62% from the prior year.
• Operating Leases declined to $7.1 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.7 million in Q4 2024 to a low of $7.1 million in Q1 2026.
• A 3-year average of $7.9 million and a median of $7.9 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases dropped 14.62% in 2025 and fell 15.79% in 2026, its largest moves.
• Tracing SION's Operating Leases over 3 years: stood at $8.7 million in 2024, then dropped by 14.62% to $7.4 million in 2025, then retreated by 4.77% to $7.1 million in 2026.
• Business Quant data shows SION's Operating Leases at $7.1 million in Q1 2026, $7.4 million in Q4 2025, and $7.8 million in Q3 2025.